CoChat

Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis

Open access
Wu, D., Li, L., Liu, C. · 2014 · Diabetes, Obesity and Metabolism
Cited by 130

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Aims: This meta‐analysis was performed to provide an update on the efficacy and safety of dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus ( T2DM ). Methods: We conducted a search on MEDLINE , Embase and Cochrane Collaborative database for randomized controlled trials ( RCTs ) of DPP ‐4 inhibitors and metformin as initial combination therapy or as monotherapy in patients with T2DM by the end of December 2012, using the key words ‘alogliptin’, ‘dutogliptin’, ‘linagliptin’, ‘saxagliptin’, ‘sitagliptin’, ‘vildagliptin’ and ‘metformin’. RCTs were selected for meta‐analysis if (1) they were RCTs comparing DPP ‐4 inhibitors plus metformin as initial combination therapy or DPP ‐4 inhibitor monotherapy to metformin monotherapy, (2) duration of treatment was ≥12 weeks and (3) reported data on haemoglobin A1c ( HbA1c ) change, fasting plasma glucose ( FPG ) change, weight change, adverse cardiovascular ( CV ) events, hypoglycaemia or gastrointestinal adverse events ( AEs ). Results: A total of eight RCTs were included. Compared with metformin monotherapy, DPP ‐4 inhibitors monotherapy was associated with lower reduction in HbA1c level [weighted mean differences ( MD ) = 0.28, 95% confidence intervals ( CIs ) (0.17, 0.40), p < 0.00001], lower reduction in FPG level [ MD = 0.81, 95% CI (0.60, 1.02), p <0.00001], lower weight loss [ MD = 1.51, 95% CI (0.89, 2.13), p < 0.00001], but lower risk of adverse CV events [risk ratio ( RR ) = 0.36, 95% CI (0.15, 0.85), p = 0.02], lower risk of hypoglycaemia [ RR = 0.44, 95% CI (0.27, 0.72), p = 0.001] and lower risk of gastrointestinal AEs [ RR = 0.63, 95% CI (0.55, 0.70), p <0.00001]. Compared with metformin monotherapy, DPP ‐4 inhibitors plus metformin as initial combination therapy was associated with higher reduction in HbA1c level [ MD = −0.49, 95% CI (−0.57, −0.40), p < 0.00001], higher reduction in FPG level [ MD = −0.80, 95% CI (−0.87, −0.74), p < 0.00001], lower weight loss [ MD = 0.44, 95% CI (0.22, 0.67), p = 0.0001]; but was not associated with a further reduction in adverse CV events [ RR =0.54, 95% CI (0.25, 1.19), p = 0.13], nor the higher risk of hypoglycaemia [ RR = 1.04, 95% CI (0.72, 1.50), p = 0.82], nor the prolonged risk of gastrointestinal AEs [ RR = 0.98, 95% CI (0.88, 1.10), p = 0.77]. Conclusions: DPP ‐4 inhibitors, which are safe and effective in controlling the blood glucose, may possibly decrease the risk of CV events in patients with T2DM . It could be a credible alternative for T2DM patients who, for some reason, cannot use metformin, or are in high risk of CV exposure. High‐quality, large sample and long‐term follow‐up clinical trails are needed to confirm the long‐term conclusions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12174

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 130

Metadata

Authors
Wu, D., Li, L., & Liu, C.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2013-07-16
Volume
16
Issue
1
Pages
30-37
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1981713709
Cited by
130
References
4
FWCI
10.85
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.